Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry

doi:10.1155/2019/2509129

Paper

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry

Published Aug 29, 2019 · G. Calapai, C. Mannucci, I. Chinou

Evidence-based Complementary and Alternative Medicine : eCAM

Q2 SJR score

20

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Background Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective The aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD in psychiatric patients. Methods This review collects the main scientific findings on the potential role of CBD in the psychiatric field, and results of clinical trials carried out on psychiatric patients are commented. A research was conducted in the PUBMED, SCOPUS, and ScienceDirect databases using combinations of the words cannabidiol, psychiatry, and neuropsychiatric. Results Preclinical and clinical studies on potential role of CBD in psychiatry were collected and further discussed. We found four clinical studies describing the effects of CBD in psychiatric patients: two studies about schizophrenic patients and the other two studies carried out on CBD effects in patients affected by generalized social anxiety disorder (SAD). Conclusion Results from these studies are promising and suggest that CBD may have a role in the development of new therapeutic strategies in mental diseases, and they justify an in-depth commitment in this field. However, clinical evidence we show for CBD in psychiatric patients is instead still poor and limited to schizophrenia and anxiety, and it needs to be implemented with further studies carried out on psychiatric patients.

Systematic Review

Rigorous Journal

Study Snapshot

Cannabidiol shows promising results in preclinical and clinical studies for schizophrenia and anxiety, but more research is needed for broader applications in psychiatric patients.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry

Sign up to use Study Snapshot

References

Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors

Herbal preparations of medical cannabis are easy to handle and self-administer, offering a practical guide for prescribing doctors on their medical indications, routes of administration, and recommended dosages.

Cannabinoids, Blood–Brain Barrier, and Brain Disposition

CBD shows potential therapeutic potential for treating ischemic and inflammatory central nervous system diseases by modifying blood-brain barrier dysfunction and protecting cerebrovascular structure and function.

Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives

Treatment resistant schizophrenia (TRS) is a significant proportion of schizophrenia patients who continue to have symptoms and poor outcomes despite treatment, with current treatment strategies focusing on clozapine and pharmacological and non-pharmacological augmentation.

Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms

Cannabidiol (CBD) shows both rapid and sustained antidepressant effects in animal models, with potential mechanisms including serotonergic, glutamatergic, and endocannabinoid systems.

Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.

Cannabidiol (CBD) shows promising potential in treating rare forms of epilepsy and autism spectrum disorders, with mixed results in experimental animal models.

Citations

Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential

Plant-derived compounds quercetin, CBD, and DMT show promising neuroprotective potential through different mechanisms of action, offering potential therapeutic benefits when combined or targeting different stages of neurodegenerative diseases.

Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia

Individuals with first-episode schizophrenia and a history of cannabis use show higher cognitive control performance, with higher dorsolateral prefrontal cortex activity during cognitive control tasks.

Matrix Metalloproteinase-9 inhibitors as therapeutic drugs for traumatic brain injury

MMP-9 inhibitors show potential as therapeutic drugs for preventing secondary brain damage after traumatic brain injury by targeting blood-brain barrier dysfunctions.

Long-term Effects of Cannabidiol and/or Fentanyl Exposure in Rats Submitted to Neonatal Pain.

A combination of fentanyl and CBD during the first week of life significantly impacts adult anxiety behavior and supraspinal pain sensitivity, with sex differences observed.

Pharmacovigilance of unlicensed cannabidiol in European countries

Unlicensed CBD use in Europe is associated with serious adverse reactions, particularly in men and adults, and should be accompanied by appropriate monitoring and precautions.

Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase

CBD's interactions with serotonin 5-HT1A receptors may explain the occurrence of insomnia in patients, with disproportionality signals found for weight decreased, hypophagia, and insomnia.

Daily associations with cannabis use and sleep quality in anxious cannabis users

Cannabis use is associated with better sleep quality, particularly for individuals with affective symptoms and using edibles with high CBD concentrations.

Pharmacovigilance on cannabidiol as an antiepileptic agent

Cannabidiol (CBD) shows potential as an antiepileptic agent, but proper monitoring of potential adverse effects is crucial, including epilepsy aggravation, hepatic disorders, lack of efficacy, and somnolence.

Effects of Cannabidiol on Locomotor Activity

CBD has potential effects on locomotor activity, but its effects on diseases and other substances require further research.